Faron Pharmaceuticals Oy (LON:FARN) Shares Cross Above 50 Day Moving Average - Time to Sell?

Faron Pharmaceuticals Oy (LON:FARN - Get Free Report) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 218.04 ($2.96) and traded as high as GBX 220 ($2.99). Faron Pharmaceuticals Oy shares last traded at GBX 214 ($2.91), with a volume of 13,867 shares.

Faron Pharmaceuticals Oy Stock Down 5.8%

The company has a current ratio of 1.45, a quick ratio of 1.09 and a debt-to-equity ratio of 922.55. The company has a market cap of £271.93 million, a price-to-earnings ratio of -5.42 and a beta of 0.36. The firm's fifty day simple moving average is GBX 218.35 and its 200 day simple moving average is GBX 200.35.

Insider Buying and Selling at Faron Pharmaceuticals Oy

In other news, insider Markku Jalkanen sold 600,000 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of GBX 310 ($4.21), for a total transaction of £1,860,000 ($2,526,830.59). Corporate insiders own 31.82% of the company's stock.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.